Isoniazid resistance among Bacillus Calmette Guerin strains: Implications on bladder cancer immunotherapy related infections

Canadian Journal of Urology

Volumn 18, Issue 3, 2011, Pages 5671-5675

  Malhotra, Prashant ^a   Farber, Bruce F ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

BCG; Connaught; Isoniazid; Resistance

Indexed keywords

ANTIINFECTIVE AGENT; ISONIAZID;

ANTIBIOTIC RESISTANCE; BLADDER TUMOR; CLASSIFICATION; DOSE RESPONSE; DRUG EFFECT; HUMAN; IMMUNOTHERAPY; MYCOBACTERIUM BOVIS; PHYSIOLOGY; REVIEW; TRANSITIONAL CELL CARCINOMA;

ANTI-BACTERIAL AGENTS; CARCINOMA, TRANSITIONAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; IMMUNOTHERAPY; ISONIAZID; MYCOBACTERIUM BOVIS; URINARY BLADDER NEOPLASMS;

EID: 80055068067     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Alexandroff AB, Jackson AM, O'Donnell MA et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353(9165):1689-1694.
2. Morales A, Edinger D, Bruce AW. Intracavity bacillus Calmette Guerin in the treatment of superficial bladder tumors. J Urol 1976;116(2):180-183.
3. Lamm DL, Thor DE, Harris SC et al. Bacillus Calmette- Guerin immunotherapy of superficial bladder cancer. J Urol 1980;124(1):38-40.
4. Prescott S, Jackson AM, Hawkyard SJ et al. Mechanisms of action of intravesical Bacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis 2000;31(Suppl 3):S91-S93.
5. Jackson AM, James K. Understanding the most successful immunotherapy for cancer. Immunologist 1994;2:208-215.
6. Prescott S, James K, Hargreave TB et al. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992;147(6):1636-1642.
7. Ritz N, Curtis N. Non tuberclous mycobacteria: mapping the global use of different BCG vaccine strains. Tuberculosis (Edinb) 2009;89(4):248-251
8. Ritz, N. Hanekom WA, Robins-Browne R, Britton WJ et al. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 2008;32(5):821-841.
9. Ritz N, Tebruegge M, Connell TG, Sievers A et al. Susceptibility of mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother 2009;53(1):316-318.
10. Shishido Y, Mitarai S, Otomo K et al. Anti-tuberculosis drug susceptibility testing of Mycobacterium bovis BCG Tokyo strain. Int J Tuberc Lung Dis 2007;11(12):1334-1338.
11. Sylvester R, Van der Meijden A, Lamm D. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168(5):1964-1970.
12. Gonzalez OY, Musher DM, Brar I et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003;36(2):140-148.
13. Shelley MD, Court JB, Kynaston H et al. Intravesical Bacillus Calmette-Guérin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000;(4):CD001986.
14. Lamm DL. Efficacy and safety of Bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31(3):S86-S90.
15. Vegt PDJ, van der Meijden APM, Sylvester R et al. Does isoniazid reduce side effects of intravesical Bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol 1997;157(4):1246-1249.
16. Goraya JS, Virdi VS. Treatment of Calmette-Guerin bacillus adenitis: a metaanalysis. Pediatr Infect Dis J 2001;20(6):632-634.
17. Dureka C, Rüsch-Gerdes S, Jocham D et al. Böhlea sensitivity of BCG to modern antibiotics. Eur Urol 2000;37(Suppl 1):21-25.
18. Shimizu T, Yasumoto T, Tatano Y et al. In vitro drug susceptibility of Mycobacterium bovis BCG Connaught and Tokyo strains. J Infect 2010;60(3):248-251.
19. Golub V, Malhotra P, Patel S. Mycobacterial brain tuberculoma due to Bacille Calmette-Guerin (BCG) intravesical chemotherapy for bladder cancer: a case report and review of literature. Can J Infect Dis Med Microbiol:In Press.
20. Parsons LM, Brosch R, Cole ST et al. Rapid and simple approach for identification of mycobacterium tuberculosis complex isolates by PCR-based genomic deletion. Analysis. J Clin Microbiol 2002;40(7):2339-2245.
21. World Health Organization. Isoniazid resistance of bacille Calmette-Guerin strains. Wkly Epidemiol Rec 2005;80:244.
22. Musser JM, Kapur V, Williams DL et al. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazidresistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996;173(1):196-202.
23. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995;8(4):496-514.
24. Banerjee A, Dubnau E, Quemard A et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263(5144):227-230.
25. Abe C, Kobayashi I, Mitarai S et al. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J Clin Microbiol 2008;46(7):2263-2268.
26. Schaaf HS, Parkin DP, Seifart HI et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005;90(6):614-618.
27. Centers for Disease Control and Prevention. Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR 2003;52(RR-11):1-77.
28. East African/British Medical Research Council Pyrazinamide Investigation. A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969;50(2):81-112.
29. Hesseling AC, Schaaf HS, Victor T et al. Resistant mycobacterium bovis bacillus Calmette-Guerin disease: implications for management of bacillus Calmette-Guerin disease in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004;23(5):476-479.